Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Feb 11, 2020
AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus
Feb 05, 2020
AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies
Dec 11, 2019
AIM ImmunoTech to Present at the Investor Summit in Philadelphia
Dec 04, 2019
AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020
Nov 15, 2019
CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019
Nov 15, 2019
AIM ImmunoTech Provides Business Update for the Third Quarter of 2019
Oct 23, 2019
AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
Oct 07, 2019
AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified
Sep 25, 2019
AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering
Sep 24, 2019
AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center
5
6
7
8
9
10
11
12
13
14
15
<<
<
>
>>
Privacy